Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Guyader, Charlotte ^a   Céraline, Jocelyn ^b   Gravier, Eléonore ^a,c,d   Morin, Aurélie ^e   Michel, Sandrine ^f   Erdmann, Eva ^b   de Pinieux, Gonzague ^g   Cabon, Florence ^e   Bergerat, Jean Pierre ^b   Poupon, Marie France ^a   Oudard, Stéphane ^h,i  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c INSERM   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e CNRS   (France)

^f Biomarker Research and Validation Department   (France)

^g SERVICE DE DERMATOLOGIE   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; DEGARELIX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FLUTAMIDE; GONADORELIN AGONIST; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER INHIBITION; CASTRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; HISTOLOGY; HORMONE ESCAPE; HORMONE RESPONSE; IN VIVO STUDY; MALE; MONITORING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANDROGENS; ANIMALS; BASE SEQUENCE; CASTRATION; CLUSTER ANALYSIS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; GENE DOSAGE; HUMANS; MALE; MICE; MUTATION; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 84864709259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042252     Document Type: Article

References (43)

1. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. ((2011)) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005.
2. Scher HI, Sawyers CL, ((2005)) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253-8261.
3. Ryan CJ, Tindall DJ, ((2011)) Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29:3651-3658.
4. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. ((2004)) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
5. Feldman BJ, Feldman D, ((2001)) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
6. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, et al. ((2009)) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15:559-565.
7. Nupponen NN, Visakorpi T, ((2000)) Molecular cytogenetics of prostate cancer. Microsc Res Tech 51:456-463.
8. Taplin ME, ((2007)) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4:236-244.
9. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP, ((2006)) Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A 103:15969-15974.
10. Guo Z, Dai B, Jiang T, Xu K, Xie Y, et al. ((2006)) Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10:309-319.
11. Culig Z, Steiner H, Bartsch G, Hobisch A, ((2005)) Mechanisms of endocrine therapy-responsive and-unresponsive prostate tumours. Endocr Relat Cancer 12:229-244.
12. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, et al. ((1994)) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478.
13. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, et al. ((2006)) Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66:5723-5728.
14. Minner S, Jessen B, Stiedenroth L, Burandt E, Kollermann J, et al. ((2010)) Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 16:1553-1560.
15. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, et al. ((1999)) Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59:5030-5036.
16. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, et al. ((2007)) Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 13:3860-3867.
17. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, et al. ((2000)) Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275:24500-24505.
18. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, et al. ((2000)) HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841-6845.
19. de Pinieux G, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Goncalves R, et al. ((2001)) Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol 159:753-764.
20. Doehn C, Sommerauer M, Jocham D, ((2006)) Drug evaluation: Degarelix-a potential new therapy for prostate cancer. IDrugs 9:565-572.
21. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, et al. ((2007)) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13:3989-3998.
22. Ceraline J, Erdmann E, Erbs P, Deslandres-Cruchant M, Jacqmin D, et al. ((2003)) A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer. Eur J Endocrinol 148:99-110.
23. Marcias G, Erdmann E, Lapouge G, Siebert C, Barthelemy P, et al. ((2010)) Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 31:74-80.
24. Legrier ME, Guyader C, Ceraline J, Dutrillaux B, Oudard S, et al. ((2009)) Hormone escape is associated with genomic instability in a human prostate cancer model. Int J Cancer 124:1103-1111.
25. Rouveirol C, Stransky N, Hupe P, Rosa PL, Viara E, et al. ((2006)) Computation of recurrent minimal genomic alterations from array-CGH data. Bioinformatics 22:849-856.
26. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet 346:265-269.
27. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, et al. ((2009)) Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group. Eur Urol.
28. J. M Crook, C. J O'Callaghan, K Ding, G Duncan, D. P Dearnaley,et al. (2011) A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013). ASCO annual meeting: Abstract 4514.
29. Lengauer C, Kinzler KW, Vogelstein B, ((1998)) Genetic instabilities in human cancers. Nature 396:643-649.
30. Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, et al. ((2009)) Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol 219:288-300.
31. Edwards J, Krishna NS, Witton CJ, Bartlett JM, ((2003)) Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9:5271-5281.
32. Chen G, Wang X, Zhang S, Lu Y, Sun Y, et al. ((2005)) Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Prostate 63:395-406.
33. Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, et al. ((2009)) Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy. Cancer Res.
34. Gottlieb B, Beitel LK, Wu JH, Trifiro M, ((2004)) The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 23:527-533.
35. Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, et al. ((2006)) Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int 97:170-178.
36. D'Antonio JM, Ma C, Monzon FA, Pflug BR, ((2008)) Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. Prostate 68:698-714.
37. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, et al. ((1999)) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 96:5458-5463.
38. Lin HK, Yeh S, Kang HY, Chang C, ((2001)) Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A 98:7200-7205.
39. Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, et al. ((2007)) Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocr Relat Cancer 14:601-611.
40. Mariani G, Fasolo A, De Benedictis E, Gianni L, ((2009)) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6:93-104.
41. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, et al. ((2008)) Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 27:7106-7117.
42. Schayowitz A, Sabnis G, Goloubeva O, Njar VC, Brodie AM, ((2010)) Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. Br J Cancer 103:1001-1007.
43. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, et al ((2012)) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520-529.